Skip to content

NEWGLAB Pharma

Metabolic Anti-Cancer Therapeutics

Menu

  • Home
    • Philosophy
    • History
    • Field of Business
    • Organization
    • Business Partner
  • Core Technology
    • About Cancer
    • KAT Mechanism
    • Papers
    • Patents
    • Real World Case Study
  • Products
    • Anticancer Therapeutics
    • Kofactor 1
    • Kofactor 2
  • R & D
    • Clinical Development
    • Laboratory
    • Collaborations
  • PR Center
    • News
    • Media
    • Book
    • Notice
  • Contact Us

Seminars with Georgia Medical Professionals

You are here: NEWGLAB Pharma > Blog > news > Seminars with Georgia Medical Professionals

Seminars with Georgia Medical Professionals

news 4a

news 4b

Seminars with Georgia Medical Professionals
peter 9 April 20209 April 2020 news
  • ← Seminars about Anti- Bacteria Treatment using 3BP with the University of Wroclaw, Poland.
  • NCI and NIH Mitochondria Interest Group Seminar →

News

  • FDA Approval Granted to Begin Clinical Trial

    FDA Approval Granted to Begin Clinical Trial

    26 January 2022
    FDA Approval Granted to Begin Clinical Trial KoDiscovery, LLC and NewG Lab Pharma, LLC have submitted the …Read more
  • Three New KOfactor 1 Advanced Products Are Now Available

    Three New KOfactor 1 Advanced Products Are Now Available

    26 January 2022
    Three New KOfactor 1 Advanced Products Are Now Available Dr. Ko has further enhanced the …Read more
  • Orphan drug designation (ODD) for "treatment of stage IIb-IV melanoma" by FDA

    Orphan drug designation (ODD) for "treatment of stage IIb-IV melanoma" by FDA

    6 May 2020
    Orphan drug designation (ODD) for "treatment of stage IIb-IV melanoma" by FDA As of May …Read more

PR Center

  • book
  • media
  • news

United States

  • NEWGLAB PHARMA, INC.
  • Address: 701E. Pratt Street, Baltimore, MD 21202
  • Office: (+1) 443-887-4080
  • Lab: (+1) 443-887-4081
  • Fax: (+1) 410-234-8896
  • Email: contact@newglabpharma.com
  • Website: www.newglabpharma.com

Korea

  • NEWGLAB PHARMA KOREA Co., Ltd.
  • Address: 13F, 479, Bongeunsa-ro, Gungnam-gu, Seoul, Korea (06095)
  • Email: contact@newglabpharma.com
  • Website: www.newglabpharma.com

Recent News

  • FDA Approval Granted to Begin Clinical Trial

    FDA Approval Granted to Begin Clinical Trial

    26 January 2022
  • Three New KOfactor 1 Advanced Products Are Now Available

    Three New KOfactor 1 Advanced Products Are Now Available

    26 January 2022
  • Orphan drug designation (ODD) for "treatment of stage IIb-IV melanoma" by FDA

    Orphan drug designation (ODD) for "treatment of stage IIb-IV melanoma" by FDA

    6 May 2020
  • Acquired ODD status and License-In for additional Indications

    Acquired ODD status and License-In for additional Indications

    27 April 2020
  • Dietary supplement sales contract with KoDiscovery and Sales started in March

    Dietary supplement sales contract with KoDiscovery and Sales started in March

    27 April 2020

Suggested Links

  • Original website
  • Kofactor store

Visitors Counter

636611

Copyright © 2026 NEWGLAB Pharma. All rights reserved. Website made by Piotr Ułaszewski.
  • Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.